ValiRx given international showcase at prestigious American cancer event
The drug developer ValiRx (LON:VAL) has been asked to give a presentation at the prestigious American Association for Cancer Research Conference in Washington starting this Saturday (April 6)....
View ArticleValiRx granted patent in Australia for top compound
ValiRx (LON:VAL) has been granted patent protection in Australia for VAL201, its lead therapeutic compound that targets at a range of cancers. The company already has full, worldwide rights and...
View ArticleValiRx looks to social impact market as becomes founder member of new exchange
Cancer focused diagnostic specialist ValiRx (LON:VAL) is looking forward to being a member of the new Social Stock Exchange (SSE), where investors can learn more about firms with social and...
View ArticleUPDATE- ValiRx agrees details of cancer study
---ADDS QUOTES FROM COMPANY, SHARE PRICE--- ValiRx (LON:VAL) said its agreed an expanded and adaptive protocol for its first-in-man studies on VAL 201, its drug candidate being developed for prostate...
View ArticleValiRx's lead compound trial progresses on schedule
Drug developer ValiRx (LON:VAL) is making steady progress with the first in-man studies for lead compound VAL201. The phase I trial is to assess tolerability and safety of the prostate cancer treatment...
View ArticleValiRx's €1.6mln Eurostars grant provides endorsement of its technology
ValiRx (LON:VAL) said it and Pharmatest Services will share a new Eurostars grant worth up to €1.6mln that will fund pre-clinical studies on its drug candidate VAL101, which regulates rebellious genes....
View ArticleValiRx interims reveal a period of 'encouraging progress'
Life sciences group ValiRx (LON:VAL) has confirmed it expects to release results from the clinical trial of its lead drug in December. VAL 201 is currently undergoing first-in-man studies on cancer...
View ArticleValiRx cashes in on VolitionRx stake
Drug developer ValiRx (LON:VAL) has sold its shareholding in VolitionRx. The life sciences firm offloaded 510,811 shares, netting US$601,578. The funds will be used to continue clinical development of...
View ArticleValiRx's stake sale provides cash run-way, says Daniel Stewart
The proceeds from ValiRx's (LON:VAL) VolitionRx stake sale along with recent fundraising strengthens the firm's balance sheet and provides a cash run-way into 2015, reckons house broker Daniel Stewart....
View ArticleValirX gets new European grant for cancer screening biomarker
ValiRx (LON:VAL) has received European patent approval for its cancer screening test biomarker NAV3. The test enables cancer cells to be detected in tissue samples at a stage where tumour development...
View Article